Drugs / Universal Donor Expanded TGF-beta-imprinted NK Cells
Universal Donor Expanded TGF-beta-imprinted NK Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07144384 | Oct 2025 → Apr 2026 | nodular basal cell carcinoma, skin squamous cell carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06203912 | Mar 2024 → May 2026 | plasma cell myeloma | Elvira Umyarova | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06026657 | Apr 2024 → Dec 2026 expected | Her2-receptor negative breast cancer | Margaret Gatti-Mays | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal Donor Expanded TGF-beta-imprinted NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06203912 ↗ |
| Action | Deplete | “NK cells can recognize missing or incorrect proteins on tumor cells and then eliminate these tumor cells” NCT06026657 ↗ |
| Modality | Cell therapy | “TGFBi NK cells are manufactured cells that are a part of your natural immunity.” NCT06026657 ↗ |
| Route | Intravenous | “Patients receive TGFBi NK cells IV over 10-30 minutes on day 16 of cycle 1” NCT06026657 ↗ |